TR-FRET-based KRAS [G13D]/CRBN PROTAC interaction detection technology

The KRAS gene is the most frequently mutated member of the RAS family and plays a key driving role in the development and progression of various malignant tumors. Among the known KRAS mutation types, the G13D mutation is relatively common, characterized by the substitution of glycine at position 13 with aspartic acid, leading to a significant reduction in GTPase hydrolysis activity and keeping the protein in a persistently GTP-bound activated state. This mutation promotes abnormal cell proliferation and survival by continuously activating downstream signaling pathways such as MAPK and PI3K. Traditional targeting strategies have primarily focused on the GTP-binding pocket or downstream effector molecules, but the development of direct inhibitors has long faced challenges due to the relatively smooth surface of the KRAS protein and the lack of deep hydrophobic pockets.

In recent years, PROTAC technology has garnered widespread attention as a novel targeted protein degradation strategy. PROTAC molecules simultaneously bind to the target protein and E3 ubiquitin ligase, inducing ubiquitination of the target protein, which is then recognized and degraded by the proteasome. CRBN is one of the commonly used E3 ligases in PROTAC design. To evaluate whether PROTAC molecules can effectively mediate the interaction between KRAS [G13D] and CRBN, a reliable in vitro detection system is required. TR-FRET technology, with its homogeneous, high-sensitivity, and wash-free operation characteristics, is suitable for detecting PROTAC-induced ternary complex formation. Based on these requirements, the TR-FRET detection kit for KRAS [G13D] and CRBN interactions has emerged, providing an important standardized tool for research in this field.

The design of this kit is based on the core principle of time-resolved fluorescence resonance energy transfer. TR-FRET combines the long-lived fluorescence characteristics of time-resolved fluorescence with the distance sensitivity of fluorescence resonance energy transfer, effectively eliminating interference from short-lived background fluorescence. In the kit system, the donor fluorophore is typically a chelate of europium or terbium, with a fluorescence lifetime in the millisecond range; the acceptor fluorophore employs near-infrared fluorescent dyes.

When PROTAC molecules are present in the system and simultaneously bind to KRAS [G13D] protein and CRBN protein, two specific antibodies labeled with donor and acceptor fluorophores are brought within a distance of less than 10 nanometers. Under excitation light of a specific wavelength, the donor fluorophore is excited and emits long-lived fluorescence. If the distance between the donor and acceptor is sufficiently close, the donor's emission spectrum overlaps with the acceptor's excitation spectrum, and the donor's energy is transferred non-radiatively to the acceptor, which then emits fluorescence at a specific wavelength. Conversely, if the PROTAC molecule fails to bridge the two proteins effectively, the donor and acceptor remain too far apart for energy transfer to occur. By measuring the ratio of acceptor fluorescence signal to donor fluorescence signal, the efficiency of PROTAC-induced ternary complex formation between KRAS [G13D] and CRBN can be quantitatively assessed.

The main components of this kit typically include the following categories: recombinantly expressed KRAS [G13D] mutant protein, recombinantly expressed CRBN protein or CRBN-containing cell lysate, donor-labeled anti-KRAS specific antibody, acceptor-labeled anti-CRBN specific antibody, and an optimized reaction buffer system. Some kits also provide positive and negative controls to validate the reliability of the experimental system.

The standard operational workflow is as follows: First, add the test PROTAC molecules at predetermined concentration gradients to the reaction wells; then, sequentially add KRAS [G13D] protein and CRBN protein, incubate at an appropriate temperature for a set duration to allow PROTAC-mediated ternary complex formation; next, simultaneously add the donor-labeled anti-KRAS antibody and acceptor-labeled anti-CRBN antibody and continue incubation; finally, use a plate reader compatible with TR-FRET detection to measure donor and acceptor fluorescence signals at specific wavelengths and calculate their ratio. The entire process requires no washing steps, significantly reducing operational errors and human interference while increasing throughput.

Under optimized experimental conditions, this kit exhibits ideal detection performance. The detection window, i.e., the signal-to-background ratio, is typically greater than 5, indicating clear differentiation between positive signals and negative background. The Z' factor, a common metric for evaluating the reliability of homogeneous detection systems, is generally above 0.6 for this kit, demonstrating good stability and reproducibility suitable for medium- to high-throughput screening applications. The half-maximal effective concentration can be reliably detected at the nanomolar level, with a linear detection range typically spanning over two orders of magnitude, meeting the comparative needs of PROTAC molecules with varying activity strengths. Both intra-assay and inter-assay coefficients of variation are controlled at low levels, ensuring comparability across different batches of experimental data.

The TR-FRET KRAS [G13D]/CRBN PROTAC kit provides a standardized in vitro detection tool for research on targeted degradation of mutant KRAS. Based on the TR-FRET principle, it enables homogeneous, high-sensitivity quantitative analysis of PROTAC-induced ternary complex formation efficiency. This kit has clear practical value in screening and mechanistic studies, but users should also be aware of the gap between in vitro detection and cellular degradation, designing experiments rationally and interpreting results scientifically.

The "UniOne® TR-FRET Human KRAS[G13D]/CRBN PROTAC Binding Kit (GDP/GTP load)" (Catalog Number: UA086004), independently developed by Nanjing UA-Bio Technology Co., Ltd. (UA-Bio), is a high-performance analytical platform specifically designed for studying PROTAC molecules that target the KRAS G13D mutant protein and induce interactions between KRAS G13D and the CRBN (Cereblon) E3 ubiquitin ligase. This kit is based on time-resolved fluorescence resonance energy transfer (TR-FRET) technology and supports the evaluation of PROTAC-mediated ternary complex formation between KRAS G13D and CRBN under GDP- or GTP-loaded states. It provides a stable and reliable standardized solution for applications such as targeted protein degradation (PROTAC) technology development, anticancer drug screening, and mutant-specific degrader research.

Nanjing UA-Bio Technology Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or specific application inquiries regarding the "UniOne® TR-FRET Human KRAS[G13D]/CRBN PROTAC Binding Kit (GDP/GTP load)" (Catalog Number: UA086004), please feel free to contact us.